Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Paris, France, and Tarrytown, N.Y. - September 26, 2016 - Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news